# PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY							
То:		PCT					
Patenttitoimisto							
Kari Pirhonen Oy		WRIT	TEN OPINION OF THE				
P.O. Box 71		INTERNATIONAL SEARCHING AUTHORITY					
FIN-20101 TURKU							
FINLAND		•	(PCT Rule 43bis.1)				
		Date of mailing					
		(day/month/year)	<b>0</b> 3 <b>-</b> 03- 2005				
Applicant's or agent's file reference		FOR FURTHER ACTION					
P1967		See paragraph 2 below					
International application No.	International filing dat	e (day/month/year)	Priority date (day/month/year)				
PCT/IB2004/003432	20.10.2004		20.10.2003				
International Patent Classification (IPC) o	or both national classifi	cation and IPC					
B03C 1/00, B03C 1/28,			:				
Applicant							
Bio-Nobile Oy et al			••				
1. This opinion contains indications relat	ting to the following it	ems:					
Box No. I Basis of the opin	nion						
Box No. II Priority							
Box No. III Non-establishme	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
Box No. IV Lack of unity of	invention						
Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement							
Box No. VI Certain documents cited							
Box No. VII Certain defects i	Box No. VII Certain defects in the international application						
Box No. VIII Certain observations on the international application							
2. FURTHER ACTION							
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered.							
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.  For further opinions, see Form PCT/ISA/220.							

Name and mailing address of the ISA/SE Patent- och registreringsverket Box 5055

Authorized officer

S-102 42 STOCKHOLM

Teija Rasch

Facsimile No. +46 8 667 72 88

Telephone No. +46 8 782 25 00

3. For further details, see notes to Form PCT/ISA/220.

# BEST AVAILABLE COPY

# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/IB2004/003432

Во	x No. I	Basis of this opinion
1.	which it	ard to the language, this opinion has been established on the basis of the international application in the language in was filed, unless otherwise indicated under this item.  his opinion has been established on the basis of a translation from the original language into the following language,
	aı	, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2.	claimed i	ard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the nvention, this opinion has been established on the basis of:
	a. type c	of material a sequence listing
		table(s) related to the sequence listing
	b. format	of material
		in written format
	<u></u>	in computer readable form
	c. time c	of filing/furnishing
		contained in the international application as filed.
		filed together with the international application in computer readable form.
		furnished subsequently to this Authority for the purposes of search.
3.		In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Addition	al comments:
!		

### WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/IB2004/003432

Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
1. Statemen	nt					
Nove	lty (N)	Claims		YES		
		Claims	1-3	NO		

Inventive step (IS) Claims Claims 1-3 NO

1-3 Industrial applicability (IA) Claims

Claims

## 2. Citations and explanations:

The invention according to claims 1-3 relates to a magnetic enrichment method in which method the desired biological component is collected from a solution by means of a magnet, which component is thereafter concentrated in a liquid. The invention further relates to a reactor unit for micro particles and to a magnet unit.

The aim of the invention is to solve the problem with performing enrichment from a large volume to a little volume by means of micro particles in a simple and efficient way.

The following documents are cited in the International Search Report:

D1: US 6409925 B1

D2: WO 8705536 A1 D3: US 6040192 A

D4: US 6596162 B2

D5: US 5053344 A

D6: US 2003/0062314 A1

D7: WO 03044537 A1

D8: EP 1162444 A1

D9: DE 10063984 A1

### Claim 1

Each of the documents D1-D4 shows a magnetic enrichment method wherein the desired biological component is collected from the solution by means of a magnet, which component is thereafter enriched in a liquid. At least one biological

. . . / . . .

# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/IB2004/003432

### Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of: BOX V.

component is collected in a closed reactor vessel by means of the micro particles or at least one particle attached to the magnet. At least one biological component is enriched in such a manner that the desired component is released into the solution (see the references in the Search Report).

Therefore the invention according to claim 1 is not novel, does not involve an inventive step but is industrially applicable.

### Claim 2

Each of the documents D5-D6 shows a reactor unit for micro particles which unit is a closed vessel. It is unclear how the prevailing conditions are made controllable according to claim 2. However, it is considered that the prevailing conditions are controllable in each of the arrangements shown by the documents D5-D6 (see the references in the Search Report).

Therefore the invention according to claim 2 is not novel, does not involve an inventive step but is industrially applicable.

# Claim 3

It is unclear how the shape and the location of the magnet unit in the reactor unit are adjusted in a preferable manner to collect the desired biological component. The invention according to claim 3 does not give any technical details concerning how the magnet unit is constituted to achieve a shape and a location of a magnet unit in a preferable manner. Each of the documents D1, D2 and D7 shows that the shape and the location of the magnet unit in the reactor unit are adjusted in a suitable manner for collecting the desired biological component (see the references in the Search Report).

Therefore, the invention according to claim 3 is not novel, does not involve an inventive step but is industrially applicable.